In vitro study of potential antibacterial pometia pinnata leaf extract in Neisseria gonorrhoeae
Downloads
Additional Files
Background: Gonorrhea cases experiencing antibiotic resistance are increasing due to inadequate treatment or failure to contribute to an increase in antibiotic resistance cases; WHO suggests adding herbal therapy treatment methods is expected to minimize the occurrence of drug resistance as much as possible. Previous studies that have been carried out using other herbal plants have not shown any potential to inhibit the growth of Neisseria gonorrhoeae bacteria, seen from the amount of extract concentration and the dosage and content of the compounds in the contents monitoring the time.
Objective: To analyze the difference in the effect of various concentrations of Matoa Leafs Extract (Pometia Pinnata) compared to 500mg Levofloxacin on the increase in the growth inhibition of Neisseria gonorrhoeae.
Methods: This is true-experimental research with a post-test-only control group with a randomized design. The sample in this study was the microorganism Neisseria gonorrhoeae obtained through vaginal swabs in 2 females (FSW) positive for Gonorrhea by gram staining and microscopic examination and culture on Chocolate Agar Plant (CAP) media. The culture was then suspended in CAP media. Matoa Leaf extract concentration of 100%, 80%, 60%, 40%, 20%, positive control with Levofloxacin 500 mg and negative control with distilled water with four replications and monitoring in 24 hours, 48 hours, 72 hours, and 96 hours. Data analysis used Kruskal-Wallis, Mann-Whitney, and cohen's test.
Result: Levofloxacin 500mg in inhibiting Neisseria Gonorrhoeae bacteria is very effective, and Matoa Leaf extracts 60% and 40% P=0,026 have a strong enough potential to inhibit the growth of Neisseria gonorrhoeae bacteria with the same potential strength. The cohen's test 1.4 effect the levofloxacin 500mg provides a significant influence inhibiting Neisseria Gonorrhoeae.
Conclusion: Matoa Leaf extract 60%, and 40% have solid antibacterial potential, although not as strong as Levofloxacin 500mg.Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
